Healthtech funding in H2 2016
European Healthtech startup funding raised during H2 2016.
In H2 2016, 172 European Healthtech companies closed 180 funding rounds and raised €870M in equity funding (excluding debt and grants), down 31.8% versus H2 2015. Debt rounds added €19M. Ireland led by capital raised, and Bpifrance was the most active investor. Data as of 20 Nov 2026.
Equity funding
€870M
-31.8% vs H2 2015 · excl. debt & grants · +€19M debt
Funding rounds
180
+27.7% vs H2 2015
Companies
172
Top country
Ireland
Rank among sectors
#4
8.1% of sector funding
Debt financing
€19M
2.1% of total
Top-10 round share
45.0%
of disclosed capital
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H2 2016 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jul | €181M | 26 |
| Aug | €34M | 17 |
| Sep | €182M | 30 |
| Oct | €257M | 43 |
| Nov | €153M | 36 |
| Dec | €110M | 28 |
Top countries
by € raisedHealthtech — top countries by capital, H2 2016 — interactive chart.
Data table
| Healthtech — top countries by capital, H2 2016 | |
|---|---|
| Ireland | €175M |
| France | €133M |
| UK | €114M |
| Germany | €108M |
| Sweden | €96M |
| Switzerland | €77M |
| Russia | €55M |
| Israel | €49M |
Stage mix
by € raisedHealthtech — stage mix, H2 2016 — interactive chart.
Data table
| Healthtech — stage mix, H2 2016 | |
|---|---|
| Series A | €340M |
| Growth/Late | €192M |
| Series B | €134M |
| Early VC | €106M |
| Seed | €44M |
| Other | €33M |
| Grant | €28M |
| Series C | €21M |
| Debt | €19M |
Exits & M&A
13 Acquisition · 3 IPO16 exits · €124M disclosed.
| Creo Medical | IPO | Jul 2016 | €74M |
| Genesort | Acquisition | Dec 2016 | €21M |
| Luck Genome | Acquisition | Oct 2016 | €11M |
| Cellink | IPO | Aug 2016 | €8.1M |
| Linkcare | Acquisition | Oct 2016 | €5.0M |
| dariohealth | IPO | Nov 2016 | €4.6M |
Top deals
largest disclosed rounds in H2 2016| Company | Stage | Date | Amount |
|---|---|---|---|
| Carrick Therapeutics | Series A | Oct 2016 | €86M |
| NaPopravku | Early VC | Dec 2016 | €46M |
| Brillen.de | Growth/Late | Jul 2016 | €45M |
| IOmx Therapeutics | Series A | Sep 2016 | €40M |
| Genomics Medicine Ireland | Series A | Oct 2016 | €36M |
| Genfit | Growth/Late | Oct 2016 | €34M |
| BONESUPPORT | Growth/Late | Oct 2016 | €33M |
| OxThera | Other | Nov 2016 | €32M |
| Spineart | Growth/Late | Sep 2016 | €30M |
| Artios | Series A | Sep 2016 | €29M |
| NBE-Therapeutics | Series B | Nov 2016 | €19M |
| Cambridge Medical Robotics | Series A | Jul 2016 | €18M |
| Aspect Imaging | Growth/Late | Jul 2016 | €18M |
| Nyxoah | Series B | Jul 2016 | €18M |
| Vivasure Medical | Series C | Sep 2016 | €16M |
Top investors
most active in H2 2016, by deal count- Bpifrance5 deals
- High-Tech Gründerfonds (HTGF)4 deals
- Almi Invest3 deals
- Amadeus Capital Partners3 deals
- Bayern Kapital3 deals
- Boehringer Ingelheim Venture Fund3 deals
- Cambridge Enterprise3 deals
- Cambridge Innovation Capital3 deals
- Markeds modningsfonden - Market Maturation Fund3 deals
- Seventure Partners3 deals